The link between inhibition of SGLT2 in the kidney and reductions in clinical outcomes (hospitalizations, progression of renal disease, mortality) is multifactorial and involves diverse elements, including the inhibition of central SNS outflow and improved hemodynamics. The gene discussed is SLC5A2; the disease is kidney disorder.